CLOs on the Move

Neurotrope

www.neurotrope.com

 
Neurotrope is discovering restorative therapeutics for patients with life-altering neurodegenerative diseases and development disorders. We are a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders. Our experience and passion for novel drug therapies have enabled us to develop a pipeline that includes various treatment approaches for serious and difficult-to-treat diseases such as Alzheimer`s Disease, Fragile X Syndrome and Niemann-Pick Type C
  • Number of Employees: 25-100
  • Annual Revenue: > $1 Billion
  • www.neurotrope.com
  • 1185 Avenue of the Americas 3rd Floor
    New York, NY USA 10036
  • Phone: 973.242.0005

Executives

Name Title Contact Details
Michael Ciraolo
General Counsel Profile

Similar Companies

Merck

Today`s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside of the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.

Meier Clinics

Meier Clinics provides Christian counseling for those struggling with depression, anxiety, marriage issues, grief, ADD or ADHD, bipolar, and a variety of other issues.

BCY LifeSciences

BCY LifeSciences Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Advanced Pain Care

Advanced Pain Care is here to help your chronic and acute pain, with 11 locations across Central Texas and Amarillo. Call us and stop the pain today.

ORIC Pharmaceuticals

ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antagonist of the glucocorticoid receptor (GR), which has been implicated in resistance to various treatment modalities—including chemotherapy, immunotherapy, and anti-hormonal therapy—and across multiple cancers. The resulting product candidate, ORIC-101, is now being studied in clinical trials for a range of solid tumors. ORIC-101 and other pipeline programs are a result of rigorous, hands-on experimentation and medicinal chemistry efforts led by our internal team of scientists in biology, medicinal chemistry, DMPK and translational medicine, with assistance from academic collaborators and continued guidance from our founders and board members. This collective team maintains an unwavering focus on improving the lives of patients by tackling the problem of cancer treatment resistance.